KR101820115B1 - Ｆｓｈ의 안정화 방법 - Google Patents

Ｆｓｈ의 안정화 방법 Download PDF

Info

Publication number
KR101820115B1
KR101820115B1 KR1020137002504A KR20137002504A KR101820115B1 KR 101820115 B1 KR101820115 B1 KR 101820115B1 KR 1020137002504 A KR1020137002504 A KR 1020137002504A KR 20137002504 A KR20137002504 A KR 20137002504A KR 101820115 B1 KR101820115 B1 KR 101820115B1
Authority
KR
South Korea
Prior art keywords
rfsh
fsh
formulation
salt
preservative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137002504A
Other languages
English (en)
Korean (ko)
Other versions
KR20130143692A (ko
Inventor
헬렌 울리카 쇼그렌
헤이디 루이스 바거
Original Assignee
훼링 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훼링 비.브이. filed Critical 훼링 비.브이.
Publication of KR20130143692A publication Critical patent/KR20130143692A/ko
Application granted granted Critical
Publication of KR101820115B1 publication Critical patent/KR101820115B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
KR1020137002504A 2010-07-30 2011-07-28 Ｆｓｈ의 안정화 방법 Active KR101820115B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428.5 2010-07-30
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001203A Division KR101991756B1 (ko) 2010-07-30 2011-07-28 Ｆｓｈ의 안정화 방법

Publications (2)

Publication Number Publication Date
KR20130143692A KR20130143692A (ko) 2013-12-31
KR101820115B1 true KR101820115B1 (ko) 2018-01-18

Family

ID=43216624

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137002504A Active KR101820115B1 (ko) 2010-07-30 2011-07-28 Ｆｓｈ의 안정화 방법
KR1020187001203A Active KR101991756B1 (ko) 2010-07-30 2011-07-28 Ｆｓｈ의 안정화 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187001203A Active KR101991756B1 (ko) 2010-07-30 2011-07-28 Ｆｓｈ의 안정화 방법

Country Status (27)

Country Link
US (3) US8993732B2 (enExample)
EP (3) EP2417982A1 (enExample)
JP (3) JP5860047B2 (enExample)
KR (2) KR101820115B1 (enExample)
CN (2) CN103052398B (enExample)
AR (1) AR082776A1 (enExample)
AU (1) AU2011284702C1 (enExample)
BR (1) BR112013002312B1 (enExample)
CA (1) CA2805864A1 (enExample)
DK (1) DK2598160T3 (enExample)
ES (1) ES2623634T3 (enExample)
HR (1) HRP20170386T1 (enExample)
HU (1) HUE033592T2 (enExample)
IL (2) IL223821A (enExample)
JO (1) JO3229B1 (enExample)
LT (1) LT2598160T (enExample)
MX (2) MX356951B (enExample)
NZ (2) NZ606366A (enExample)
PL (1) PL2598160T3 (enExample)
PT (1) PT2598160T (enExample)
RS (1) RS55772B1 (enExample)
RU (1) RU2574012C2 (enExample)
SA (1) SA114350786B1 (enExample)
SI (1) SI2598160T1 (enExample)
TW (1) TWI439283B (enExample)
WO (1) WO2012013742A2 (enExample)
ZA (1) ZA201209497B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2015075743A1 (en) * 2013-11-12 2015-05-28 Cadila Healthcare Limited Formulation for gonadotropins
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
IL275148B2 (en) 2017-12-07 2025-02-01 Adocia An injectable solution with a pH of 7 comprising at least one basic insulin with a PI between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals.
KR20200106891A (ko) 2017-12-07 2020-09-15 아도시아 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285665A1 (en) 1997-01-15 2003-02-26 Akzo Nobel N.V. Liquid gonadotropin containing formulations
US20080051329A1 (en) * 1998-07-23 2008-02-28 James Arthur Hoffmann FSH and FSH variant formulations, products and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029095A1 (en) 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
CZ297042B6 (cs) * 1996-05-29 2006-08-16 Delsitechoy Dodávkové zarízení pro pomalé uvolnování biologicky úcinného cinidla, jeho pouzití a farmaceutický prostredek s jeho obsahem
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
KR101573773B1 (ko) * 2008-02-08 2015-12-02 바이오제너릭스 게엠베하 Ｆｓｈ의 액체 포뮬레이션
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
JP5808323B2 (ja) * 2009-06-22 2015-11-10 アムジエン・インコーポレーテツド 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング
EP2533800B1 (en) * 2010-02-12 2016-07-20 Intas Pharmaceuticals Ltd. Liquid formulation of follicle stimulating hormone
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285665A1 (en) 1997-01-15 2003-02-26 Akzo Nobel N.V. Liquid gonadotropin containing formulations
US20080051329A1 (en) * 1998-07-23 2008-02-28 James Arthur Hoffmann FSH and FSH variant formulations, products and methods

Also Published As

Publication number Publication date
IL223821A (en) 2017-01-31
HRP20170386T1 (hr) 2017-05-05
US20130210727A1 (en) 2013-08-15
TWI439283B (zh) 2014-06-01
CN105106939A (zh) 2015-12-02
CA2805864A1 (en) 2012-02-02
KR20180008916A (ko) 2018-01-24
AR082776A1 (es) 2013-01-09
KR101991756B1 (ko) 2019-06-21
BR112013002312B1 (pt) 2021-09-21
MX2013000681A (es) 2013-02-27
AU2011284702B2 (en) 2015-05-14
SA114350786B1 (ar) 2015-07-09
EP2598160B1 (en) 2017-02-22
RS55772B1 (sr) 2017-07-31
WO2012013742A2 (en) 2012-02-02
JP6522711B2 (ja) 2019-05-29
JO3229B1 (ar) 2018-03-08
KR20130143692A (ko) 2013-12-31
ES2623634T3 (es) 2017-07-11
TW201208694A (en) 2012-03-01
PL2598160T3 (pl) 2017-06-30
JP2016102127A (ja) 2016-06-02
US9463221B2 (en) 2016-10-11
JP5860047B2 (ja) 2016-02-16
EP2417982A1 (en) 2012-02-15
BR112013002312A2 (pt) 2018-03-20
US20150265681A1 (en) 2015-09-24
MX356951B (es) 2018-06-21
AU2011284702C1 (en) 2015-09-03
CN103052398A (zh) 2013-04-17
WO2012013742A3 (en) 2012-04-19
EP2598160A2 (en) 2013-06-05
MX341464B (es) 2016-08-22
AU2011284702A1 (en) 2013-02-07
IL249920A0 (en) 2017-03-30
NZ606366A (en) 2014-08-29
DK2598160T3 (en) 2017-03-27
PT2598160T (pt) 2017-03-30
SI2598160T1 (sl) 2017-07-31
US20170216405A1 (en) 2017-08-03
JP2013532677A (ja) 2013-08-19
CN103052398B (zh) 2015-09-16
LT2598160T (lt) 2017-04-10
HUE033592T2 (hu) 2017-12-28
NZ628962A (en) 2016-01-29
JP2018048188A (ja) 2018-03-29
ZA201209497B (en) 2013-08-28
EP3144010A1 (en) 2017-03-22
US8993732B2 (en) 2015-03-31
RU2574012C2 (ru) 2016-01-27
RU2012157154A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
KR101820115B1 (ko) Ｆｓｈ의 안정화 방법
US20250352621A1 (en) Stable liquid gonadotropin formulation
HK1184381B (en) Stabilization of fsh
HK1184381A (en) Stabilization of fsh

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170414

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20171011

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180112

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180112

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180112

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20200326

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

PR1001 Payment of annual fee

Payment date: 20210105

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220105

Start annual number: 5

End annual number: 5